Switch to:
GuruFocus has detected 6 Warning Signs with Teva Pharmaceutical Industries Ltd $TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Cash Flow from Financing
$23,182 Mil (TTM As of Mar. 2017)

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2017, Teva Pharmaceutical Industries Ltd paid $0 Mil more to buy back shares than it received from issuing new shares. It spent $1,350 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $411 Mil paying cash dividends to shareholders. It spent $7 Mil on other financial activities. In all, Teva Pharmaceutical Industries Ltd spent $1,768 Mil on financial activities for the three months ended in Mar. 2017.


Definition

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Teva Pharmaceutical Industries Ltd's Cash from Financing for the fiscal year that ended in Dec. 2016 is calculated as:

Cash from Financing(A: Dec. 2016 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred+Dividends+Other Financing
=329+26251+329+-1558+-134
=25,217

Teva Pharmaceutical Industries Ltd's Cash from Financing for the quarter that ended in Mar. 2017 is

Cash from Financing(Q: Mar. 2017 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred+Dividends+Other Financing
=0+-1350+0+-411+-7
=-1,768

Teva Pharmaceutical Industries Ltd Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2017 was 279 (Jun. 2016 ) + 25372 (Sep. 2016 ) + -701 (Dec. 2016 ) + -1768 (Mar. 2017 ) = $23,182 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

Cash from financing contains five items:

1. Net Issuance of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. If this number is positive, it means that the company has received more cash from issuing shares than it has paid to buy back shares. If this number is negative, it means that company has paid more cash to buy back shares than it has received for issuing shares.

Teva Pharmaceutical Industries Ltd's net issuance of stock for the three months ended in Mar. 2017 was $0 Mil. Teva Pharmaceutical Industries Ltd paid $0 Mil more to buy back shares than it received from issuing new shares.

2. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Teva Pharmaceutical Industries Ltd's net issuance of debt for the three months ended in Mar. 2017 was $-1,350 Mil. Teva Pharmaceutical Industries Ltd spent $1,350 Mil paying down its debt.

3. Net Issuance of Preferred:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Teva Pharmaceutical Industries Ltd's net issuance of preferred for the three months ended in Mar. 2017 was $0 Mil. Teva Pharmaceutical Industries Ltd paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

4. Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Teva Pharmaceutical Industries Ltd's cash flow for dividends for the three months ended in Mar. 2017 was $-411 Mil. Teva Pharmaceutical Industries Ltd spent $411 Mil paying cash dividends to shareholders.

5. Other Financing:
Money spent or earned by company from other financial activities.

Teva Pharmaceutical Industries Ltd's other financing for the three months ended in Mar. 2017 was $-7 Mil. Teva Pharmaceutical Industries Ltd spent $7 Mil on other financial activities.


Related Terms

Cash Flow from Operations, Cash Flow from Investing, Net Issuance of Stock, Net Issuance of Debt, Dividends, Net Issuance of Preferred


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Net Issuance of Stock 6000-99-899-1,161-497-5002,852329
Net Issuance of Debt -1581,678-1,882-1,3465,034319-2,411-1,224-39326,251
Net Issuance of Preferred 000000003,291329
Dividends -299-388-529-668-800-855-1,089-1,156-1,155-1,558
Other Financing 35681462,686119114505210-134
Cash from Financing -3621,358-2,2655733,336-1,678-3,883-2,3754,80525,217

Teva Pharmaceutical Industries Ltd Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Net Issuance of Stock 0-4390003290000
Net Issuance of Debt -557041,389-874-1,612-671925,804-266-1,350
Net Issuance of Preferred 000003290000
Dividends -272-290-288-287-290-367-376-405-410-411
Other Financing -266118-14716,617-18-64-27-25-7
Cash from Financing -593931,087-1,0904,71526727925,372-701-1,768
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK